New pill GEN-725 enters early human testing for advanced cancers

NCT ID NCT07229898

First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This early-phase study tests a new tablet called GEN-725 in 48 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must be between 18 and 75 years old and have no other standard options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)

    RECRUITING

    Jinan, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, China

  • Shanghai East Hospital

    RECRUITING

    Shanghai, China

  • The First Affiliated Hospital of Xinxiang Medical University

    RECRUITING

    Xinxiang, China

Conditions

Explore the condition pages connected to this study.